Exelixis is currently undervalued compared to its sector and historical averages, despite showing robust double-digit growth and operational strength. The company maintains high profit margins, generates strong free cash flow, and funds its growth without increasing debt, while also aggressively repurchasing shares. Its main revenue driver is the drug Cabometyx, but management is investing heavily in research and development to diversify its product portfolio and sustain future growth. An analyst reiterates a Strong Buy rating with a $55 target price, reflecting a 22% upside based on conservative valuation and solid fundamentals.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
The XRP Ledger (XRPL) has exceeded 8 million activated accounts, marking significant growth driven by institutional interest and AI integration. Originally built for fast cross-border payments, XRPL now supports tokenization of real-world assets, dec...
Ora Banda Mining Ltd (ASX:OBM) melaporkan rekor produksi emas pada kuartal Juni 2026, mencapai 39.552 ounce, sehingga total produksi setahun penuh menjadi 140.949 ounce. Perusahaan mengakhiri Juni dengan kas A$267,7 juta dan total likuiditas A$468 ju...
